272210:KRXHanwha Systems Co., Ltd. Analysis
Data as of 2026-05-27 - not real-time
₩110,700.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Hanwha Systems is posting solid top‑line growth driven by expanding defense and aerospace contracts, yet its margins remain thin and cash conversion is weak, leading to a negative free‑cash‑flow profile. The forward price‑to‑earnings multiple sits well above the industry average, suggesting the stock is priced for strong future earnings that may be difficult to deliver. Dividend yield is modest and the payout ratio approaches the upper half of earnings, raising questions about dividend sustainability. High leverage further strains the balance sheet, with debt levels far exceeding equity. Technical analysis shows the price hovering near a well‑established support zone while the 20‑day and 50‑day moving averages remain above the current price, indicating limited upside momentum. RSI sits in a neutral band and the MACD histogram has turned modestly positive, offering a slight bullish bias but not enough to offset the broader valuation concerns. Volume trends are declining, reflecting waning market participation. Volatility is elevated, and beta indicates sensitivity to broader market swings, amplifying risk in uncertain environments. The sector benefits from steady government spending, yet regulatory and geopolitical factors add layers of uncertainty. Overall, the stock appears overvalued relative to its earnings outlook and cash‑flow generation, warranting a cautious stance.
Investors should weigh the strong revenue trajectory against the high debt load, thin profitability, and elevated valuation before committing capital.
Investors should weigh the strong revenue trajectory against the high debt load, thin profitability, and elevated valuation before committing capital.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price near established support level
- neutral technical momentum
- declining trading volume
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- robust revenue growth
- high forward valuation multiple
- significant debt burden
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- overvalued pricing relative to earnings and cash flow
- persistent negative free cash flow
- elevated leverage and volatility
Key Metrics & Analysis
Financial Health
Revenue Growth17.00%
Profit Margin4.22%
P/E Ratio48.5
ROE2.24%
ROA0.83%
Debt/Equity39.35
Op. Cash Flow₩33.4B
Free Cash Flow₩-325492473856
Industry P/E30.1
Technical Analysis
TrendNeutral
RSI45.1
Support₩99,700.00
Resistance₩130,900.00
MA 20₩113,220.00
MA 50₩124,094.00
MA 200₩83,094.75
MACDBullish
VolumeDecreasing
Fear & Greed Index91.05
Valuation
Target Price₩105,541.66
Upside/Downside-4.66%
GradeOvervalued
TypeGrowth
Dividend Yield0.43%
Risk Assessment
Beta1.29
Volatility53.52%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.